Basic Info

3 Forbes Road
Lexington, MA 02421
Preferred contact:
  N/A - President/CEO
Aquila Biopharmaceuticals Inc
Business Identifier: NO Business Identifier is currently available for this company.
Public Profile:
In November 2000 Antigenics Inc. (Nasdaq: AGEN) of New York acquired Aquila Biopharmaceuticals, Inc. (Nasdaq: AQLA). Antigenics is working to develop personalized immunotherapeutics and revolutionary treatments for cancers, infectious diseases and autoimmune disorders. The companyís lead product candidate is Oncophage, a late-stage, personalized cancer vaccine being evaluated in several indications, including renal cell carcinoma and metastatic melanoma

 Synopsis: Awardee Business Condition
Year Founded 1999 First SBIR Year 2000 Date of Last Award 2001
Employee Range 150-249 VC funded? Yes IP Holdings 5-9
Revenue Range 5M-10M Private/Public Privately Held Exchange/Symbol N/A : N/A
 Most Recent SBIR Projects
Year Phase Agency Dollars Project Title
2000 1 NIH $127,989 CD1 Presented Vaccines to Prevent Chlamydia Infection
2000 1 NIH $100,000 Lipid-Based Vaccines For Staphylococcus Aureus


Media coverage